Dementia Is the UK's
Biggest Killer.
Most Cases
Are Preventable.

One in three. Why the number is not inevitable.

The Alzheimer's Society statistic is real and it is alarming. But it is not a verdict. The lifetime risk of dementia reflects the trajectory of an ageing population with a specific pattern of metabolic and lifestyle exposures — not an inescapable genetic fate.

The APOE4 genetic variant — the most well-known Alzheimer's risk gene — increases lifetime risk significantly but is present in only 25% of the population. The other 75% who develop dementia are developing it primarily through modifiable factors. And even APOE4 carriers can significantly reduce their risk through the same modifiable pathways.

A 2020 Lancet Commission on dementia prevention identified 12 modifiable risk factors accounting for approximately 40% of all dementia cases worldwide. Forty per cent. Not a marginal contribution — nearly half of all dementia cases potentially preventable through factors that are addressable with the right information at the right time.

Alzheimer's as Type 3 Diabetes — the insulin resistance connection

The Type 3 Diabetes hypothesis is not universally accepted and remains a framework rather than a settled clinical diagnosis. But the epidemiological evidence is consistent: people with Type 2 diabetes have approximately double the risk of developing Alzheimer's disease. People with insulin resistance — who have not yet crossed the diagnostic threshold for diabetes — have elevated risk proportional to the degree of resistance. And interventions that improve insulin sensitivity in midlife appear to reduce dementia risk in later life.

This is why the sliding timeline argument from the dam-bursting post applies directly here. The HOMA-IR was 1.8 at 40. The fasting insulin was elevated at 45. The HbA1c was 38 at 50. The brain was accumulating the consequences of impaired insulin signalling for twenty years before the first memory complaint at 70. The metabolic dysfunction and the neurological decline are not separate stories — they are the same story told in two different organs.

The 12 modifiable risk factors — and what you can measure

Homocysteine — the most actionable dementia risk marker almost nobody measures

Of all the functional markers associated with dementia risk, homocysteine has the strongest and most consistent evidence base — and is the most directly addressable through B-vitamin intervention.

Homocysteine is a metabolic intermediate produced from methionine during the methylation cycle. When the cycle runs efficiently, homocysteine is remethylated back to methionine (requiring folate and B12) or diverted to cysteine via transsulphuration (requiring B6). When these pathways are insufficient — due to MTHFR variants, B-vitamin deficiency, or excessive methionine intake — homocysteine accumulates.

Elevated homocysteine is directly neurotoxic through multiple mechanisms: it damages the blood-brain barrier, promotes neuroinflammation, generates oxidative stress in neural tissue, promotes tau phosphorylation (the hallmark of Alzheimer's neurofibrillary tangles), and impairs DNA methylation in neurons. Multiple large prospective studies have found that elevated homocysteine in midlife predicts dementia risk in later life with an odds ratio of approximately 1.7–2.0 for every 5 µmol/L increase.

The VITACOG trial — a randomised controlled trial published in PNAS in 2010 — found that B-vitamin supplementation (folic acid, B12, B6) in people with mild cognitive impairment significantly slowed brain atrophy compared to placebo, and that the effect was most pronounced in those with the highest baseline homocysteine. A 2019 follow-up analysis found that the protective effect was concentrated in people with adequate omega-3 status — establishing that homocysteine reduction and omega-3 supplementation work synergistically on brain health.

Homocysteine is measured on the Randox Signature blood panel. It is not measured on the standard NHS blood test. A person whose homocysteine has been 12 µmol/L for a decade — well below the NHS "normal" threshold of 15 but well above the functional optimal of 7 — has had a decade of elevated neurological risk that no NHS blood test would have detected.

The omega-3 index — DHA and the brain that built itself from fat

The brain is approximately 60% fat by dry weight. The most abundant structural fat in neural tissue is DHA — docosahexaenoic acid, the long-chain omega-3 fatty acid found in oily fish and, in smaller amounts, algae. DHA is not a supplement that might be nice to take. It is a structural component of every neuronal membrane in the brain, and its availability during neural development, maintenance, and repair determines neuronal function at the most fundamental level.

Low omega-3 index (the percentage of EPA and DHA in red blood cell membranes) is associated with smaller brain volume, reduced grey matter density, impaired cognitive function, and increased risk of dementia. The Framingham Heart Study found that people in the highest quartile of DHA status had a 47% reduced risk of developing dementia compared to those in the lowest quartile.

The VITACOG trial finding — that B-vitamin supplementation slowed brain atrophy most strongly in those with adequate omega-3 status — suggests that DHA and B vitamins operate as a functional unit for brain protection. This has direct clinical implications: addressing homocysteine without addressing omega-3 status is addressing half the picture.

Sleep — the glymphatic system and amyloid clearance

One of the most significant advances in dementia neuroscience in the past decade has been the discovery of the glymphatic system — a brain-specific waste clearance mechanism that operates primarily during slow-wave sleep. During deep sleep, the brain's interstitial fluid volume increases by approximately 60%, allowing cerebrospinal fluid to flush through the spaces between neurons and clear metabolic waste — including amyloid beta, the protein that accumulates in Alzheimer's plaques.

The implication is direct: chronic sleep deprivation — defined in most research as consistently less than 7 hours — impairs glymphatic clearance of amyloid beta and accelerates its accumulation. Studies using PET imaging have found that a single night of sleep deprivation produces measurable increases in amyloid burden in the brain. Chronic sleep deprivation produces a cumulative burden that represents a genuine pathway to dementia.

Sleep is not a lifestyle preference. In the context of brain health, it is the nightly cleaning cycle that keeps the brain clear of the protein debris that Alzheimer's disease is built from. Functional assessment of sleep quality — via DUTCH Plus (which measures melatonin and cortisol awakening response as circadian markers) and clinical sleep history — is a core component of any brain health assessment.

The functional markers that show risk a decade before symptoms

The MTHFR connection — why the folic acid fortification story matters for brain health

The folic acid fortification debate is directly relevant to dementia risk in a way that has not been widely discussed. MTHFR variants reduce the efficiency of converting folic acid to active methylfolate — the form required for homocysteine remethylation. People with C677T homozygous MTHFR consuming fortified flour daily may be accumulating unmetabolised folic acid (UMFA) while simultaneously failing to adequately remethylate homocysteine — because the synthetic form of the vitamin cannot complete the conversion their enzyme cannot perform.

The consequence: elevated homocysteine persisting despite apparently adequate folate intake, and a slow accumulation of the neurological damage that elevated homocysteine produces. This is why testing homocysteine directly — rather than inferring folate status from dietary intake or supplementation — is the essential clinical step. The question is not whether someone is taking folate. It is whether their homocysteine is in the optimal range. If it is not, the intervention is methylfolate (5-MTHF), not folic acid.

What a brain health assessment looks like at 45

A functional brain health assessment at 45 is not about finding dementia. It is about finding the precursors of dementia — the metabolic and nutritional patterns that, if left unaddressed, will accumulate into neurological risk over the following decades. At 45, those patterns are largely reversible. At 75, they may not be.

The assessment combines the Randox Signature blood panel — for homocysteine, fasting insulin, HOMA-IR, hsCRP, vitamin D, GFAP, NDKA, PARK7 — with the Metabolomix+ organic acids test for 8-OHdG, MMA (functional B12), FIGLU (functional folate), and the omega-3 fatty acids add-on for DHA status. The DUTCH Plus adds the sleep-relevant melatonin and cortisol awakening response picture. Read together, these panels give a comprehensive neurological risk profile that the NHS does not offer at any age, for any patient, without a presenting dementia diagnosis.

The intervention picture — what the evidence supports

The most evidence-backed dementia prevention interventions are, in order of evidence strength:

Homocysteine reduction: Methylfolate + methylcobalamin + P5P. The VITACOG trial data is the strongest intervention evidence in the field. Target homocysteine below 7 µmol/L. Test first — form matters, folic acid is not effective in MTHFR carriers.

Omega-3 supplementation: EPA + DHA, minimum 2g daily. Target omega-3 index above 8%. The VITACOG synergy with B-vitamin intervention is compelling — address both simultaneously. DHA specifically for neuronal membrane support. Higher EPA for the inflammatory component.

Insulin sensitivity: Resistance training, zone 2 aerobic exercise, time-restricted eating, dietary carbohydrate quality. The Type 3 Diabetes mechanism means that anything that improves peripheral insulin sensitivity also improves brain insulin signalling. This is not a minor lifestyle recommendation — it is the primary metabolic intervention for brain protection.

Sleep: 7–9 hours consistently. Glymphatic clearance requires slow-wave sleep. Sleep deprivation is not a badge of productivity — it is a modifiable dementia risk factor with a clear biological mechanism.

Blood pressure management: The midlife hypertension finding from the Lancet Commission is robust. Elevated blood pressure in midlife damages cerebrovascular endothelium and reduces cerebral blood flow — both contributing to vascular dementia and accelerating Alzheimer's pathology. Nitric oxide production (the primary endogenous blood pressure regulator) declines with age and homocysteine accumulation — connecting blood pressure management directly back to the methylation picture.

Hearing: Uncorrected hearing loss is the single largest modifiable risk factor in the Lancet Commission analysis. The mechanism is not fully understood — social isolation, cognitive load compensation, and shared pathology with vascular disease are all proposed. The practical implication: hearing loss in midlife should be assessed and addressed, not normalised.

Related reading